Please refer to important disclosures at the end of this report
Alkem Laboratories Ltd. (Alkem) is a Mumbai based pharma company engaged
in manufacturing and marketing of generic drugs, APIs and neutraceutical
products. Its ANDA pipeline has not seen strong traction this year so far, despite
which Alkem maintains guidance of high single digit ANDA launches going
ahead. This justifies the ~29-30% growth in the US business over next two years.
Alkem is expected to continue its outperformance vs. industry due to strong
growth in its acute and chronic segments. Both segments are expected to grow at
CAGR of 16% and 30% respectively in next 3 years due to higher sales of majo
brands and market share gains. Alkem’s ANDA pipeline increased 2.5x from
31 ANDAs in FY12 to 76 ANDAs in H1FY17. In next three years compan
expects increased ANDA launches on the back of approval to 2/3rd of its
pipeline. Alkem’s operating performance is expected to improve with better sales
mix (increasing exports) and market share gains in chronic segment. The
company has already seen margin improvement and with rising profitability o
US business, we estimate 70-100bps margin expansion. The company has
reduced its debt and debt to equity (D/E) stands at 0.2x in FY16 compared to
0.4x in FY15. The company has show a reduction in its working capital cycle
from 82days in FY15 to 65days in FY16 which is a positive sign. The company in
past 3 years has reported a healthy RoE of 17% and profit growth at a CAGR o
21% which is a good sign going ahead for the company. Hence Buy.
CMP `1,970
Stock Info
Net Debt (
cr) 80
Bloomberg Code
Shareholding Pattern (%)
Promoters 66.9
MF / Banks / Indian Fls 3.3
FII / NRIs / OCBs 3.7
Indian Public / Others 26.1
Abs. (%) 3m 1yr 3yr
Sensex 7.0 19.5 38.2
Alkem Lab. 19.8 50.4 NA
52 Week High / Low 2,015/1,175
Avg. Daily Volume 10,246
Market Cap (
cr) 23,557
BSE Sensex 28,156
Nifty 8,725
Face Value (
Reuters Code ALKE.BO
Vaibhav Agrawal
022 – 3935 7800 Ext: 6808
lkem Laboratories
Others | Pharmaceuticals
February 16, 2017
Alkem Laboratories | Pharmaceuticals
February 16, 2017
Research Team Tel: 022 - 39357800 E-mail: [email protected] Website:
Angel Broking Private Limited (hereinafter referred to as “Angel”) is a registered Member of National Stock Exchange of India Limited,
Bombay Stock Exchange Limited and Metropolitan Stock Exchange Limited. It is also registered as a Depository Participant with CDSL
and Portfolio Manager with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Private Limited is a
registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number
INH000000164. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing
/dealing in securities Market. Angel or its associates/analyst has not received any compensation / managed or co-managed public
offering of securities of the company covered by Analyst during the past twelve months.
This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment
decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should
make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the
companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine
the merits and risks of such an investment.
Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and
trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's
fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the
contrary view, if any.
The information in this document has been printed on the basis of publicly available information, internal data and other reliable
sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this
document is for general guidance only. Angel Broking Pvt. Limited or any of its affiliates/ group companies shall not be in any way
responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report.
Angel Broking Pvt. Limited has not independently verified all the information contained within this document. Accordingly, we cannot
testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document.
While Angel Broking Pvt. Limited endeavors to update on a reasonable basis the information discussed in this material, there may be
regulatory, compliance, or other reasons that prevent us from doing so.
This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced,
redistributed or passed on, directly or indirectly.
Neither Angel Broking Pvt. Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from
or in connection with the use of this information.
Disclosure of Interest Statement Alkem Laboratories
1. Financial interest of research analyst or Angel or his Associate or his relative No
2. Ownership of 1% or more of the stock by research analyst or Angel or associates or relatives No
3. Served as an officer, director or employee of the company covered under Research No
4. Broking relationship with company covered under Research No
Ratings (Based on expected returns Buy (> 15%) Accumulate (5% to 15%) Neutral (-5 to 5%)
over 12 months investment
: Reduce
-5% to -15%
< -15